70 related articles for article (PubMed ID: 8833356)
21. Proximal Disease Extension in Patients With Limited Ulcerative Colitis: A Danish Population-based Inception Cohort.
Burisch J; Ungaro R; Vind I; Prosberg MV; Bendtsen F; Colombel JF; Vester-Andersen MK
J Crohns Colitis; 2017 Oct; 11(10):1200-1204. PubMed ID: 28486626
[TBL] [Abstract][Full Text] [Related]
22. Systematic review with meta-analysis: proximal disease extension in limited ulcerative colitis.
Roda G; Narula N; Pinotti R; Skamnelos A; Katsanos KH; Ungaro R; Burisch J; Torres J; Colombel JF
Aliment Pharmacol Ther; 2017 Jun; 45(12):1481-1492. PubMed ID: 28449361
[TBL] [Abstract][Full Text] [Related]
23. Vedolizumab: toward a personalized therapy paradigm for people with ulcerative colitis.
Dart RJ; Samaan MA; Powell N; Irving PM
Clin Exp Gastroenterol; 2017; 10():57-66. PubMed ID: 28424557
[TBL] [Abstract][Full Text] [Related]
24. Twice-daily Budesonide 2-mg Foam Induces Complete Mucosal Healing in Patients with Distal Ulcerative Colitis.
Naganuma M; Aoyama N; Suzuki Y; Nishino H; Kobayashi K; Hirai F; Watanabe K; Hibi T
J Crohns Colitis; 2016 Jul; 10(7):828-36. PubMed ID: 26577683
[TBL] [Abstract][Full Text] [Related]
25. Medical Therapy of Active Ulcerative Colitis.
Bürger M; Schmidt C; Teich N; Stallmach A
Viszeralmedizin; 2015 Aug; 31(4):236-45. PubMed ID: 26557831
[TBL] [Abstract][Full Text] [Related]
26. Contribution of susceptibility variants at FCGR2A and 13q12 to the risk of relapse among Japanese patients with ulcerative colitis.
Asano K; Esaki M; Umeno J; Hirano A; Maehata Y; Moriyama T; Nakamura S; Matsumoto T; Kitazono T
J Gastroenterol; 2015 Nov; 50(11):1094-102. PubMed ID: 25787843
[TBL] [Abstract][Full Text] [Related]
27. Mucosal transcriptomics implicates under expression of BRINP3 in the pathogenesis of ulcerative colitis.
Smith PJ; Levine AP; Dunne J; Guilhamon P; Turmaine M; Sewell GW; OʼShea NR; Vega R; Paterson JC; Oukrif D; Beck S; Bloom SL; Novelli M; Rodriguez-Justo M; Smith AM; Segal AW
Inflamm Bowel Dis; 2014 Oct; 20(10):1802-12. PubMed ID: 25171508
[TBL] [Abstract][Full Text] [Related]
28. IL-33 promotes GATA-3 polarization of gut-derived T cells in experimental and ulcerative colitis.
Seidelin JB; Coskun M; Kvist PH; Holm TL; Holgersen K; Nielsen OH
J Gastroenterol; 2015 Feb; 50(2):180-90. PubMed ID: 25112700
[TBL] [Abstract][Full Text] [Related]
29. Anti-TNF alpha in the treatment of ulcerative colitis: a valid approach for organ-sparing or an expensive option to delay surgery?
Rizzo G; Pugliese D; Armuzzi A; Coco C
World J Gastroenterol; 2014 May; 20(17):4839-45. PubMed ID: 24803795
[TBL] [Abstract][Full Text] [Related]
30. [New biologics for treatment of chronic inflammatory bowel diseases].
Schreiber S; Bachmann O
Internist (Berl); 2014 Apr; 55(4):367-76. PubMed ID: 24619099
[TBL] [Abstract][Full Text] [Related]
31. How does genotype influence disease phenotype in inflammatory bowel disease?
Ananthakrishnan AN; Xavier RJ
Inflamm Bowel Dis; 2013 Aug; 19(9):2021-30. PubMed ID: 23644824
[TBL] [Abstract][Full Text] [Related]
32. Differential diagnosis of inflammatory bowel disease: what is the role of colonoscopy?
Jung SA
Clin Endosc; 2012 Sep; 45(3):254-62. PubMed ID: 22977813
[TBL] [Abstract][Full Text] [Related]
33. Impact of medical therapies on inflammatory bowel disease complication rate.
Reenaers C; Belaiche J; Louis E
World J Gastroenterol; 2012 Aug; 18(29):3823-7. PubMed ID: 22876033
[TBL] [Abstract][Full Text] [Related]
34. Surgical treatment of ulcerative colitis in the biologic therapy era.
Biondi A; Zoccali M; Costa S; Troci A; Contessini-Avesani E; Fichera A
World J Gastroenterol; 2012 Apr; 18(16):1861-70. PubMed ID: 22563165
[TBL] [Abstract][Full Text] [Related]
35. Pros and cons of medical management of ulcerative colitis.
Navaneethan U; Shen B
Clin Colon Rectal Surg; 2010 Dec; 23(4):227-38. PubMed ID: 22131893
[TBL] [Abstract][Full Text] [Related]
36. Current trends in inflammatory bowel disease: the natural history.
Langholz E
Therap Adv Gastroenterol; 2010 Mar; 3(2):77-86. PubMed ID: 21180592
[TBL] [Abstract][Full Text] [Related]
37. The peri-appendiceal red patch in ulcerative colitis: review of the University of Chicago experience.
Rubin DT; Rothe JA
Dig Dis Sci; 2010 Dec; 55(12):3495-501. PubMed ID: 20936357
[TBL] [Abstract][Full Text] [Related]
38. A pro-resolution mediator, prostaglandin D(2), is specifically up-regulated in individuals in long-term remission from ulcerative colitis.
Vong L; Ferraz JG; Panaccione R; Beck PL; Wallace JL
Proc Natl Acad Sci U S A; 2010 Jun; 107(26):12023-7. PubMed ID: 20547854
[TBL] [Abstract][Full Text] [Related]
39. Top-down therapy for IBD: rationale and requisite evidence.
D'Haens GR
Nat Rev Gastroenterol Hepatol; 2010 Feb; 7(2):86-92. PubMed ID: 20134490
[TBL] [Abstract][Full Text] [Related]
40. Ulcerative proctitis.
Whitlow CB
Clin Colon Rectal Surg; 2004 Feb; 17(1):21-7. PubMed ID: 20011281
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
